Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com
StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report sent to investors on Wednesday. The firm issued a sell rating on the stock. Other equities research analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $18.00 price target on […]
StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report sent to investors on Wednesday. The firm issued a sell rating on the stock. Other equities research analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $18.00 price target on […]
